More gay and bisexual men can donate blood under new FDA rules

More gay and bisexual men can donate blood under new FDA rules


Empty blood vials sit on a table at Vitalant blood donation center on January 11, 2022 in San Francisco, California.

Justin Sullivan | Getty Images

The Food and Drug Administration said Thursday that it finalized a new rule that will allow more gay and bisexual men to donate blood.

Under the latest guidelines, all potential donors would need to complete an individualized risk assessment — regardless of gender or sexual orientation. People who have had anal sex with a new partner, or more than one partner, in the last three months would be asked to wait to donate blood.

The updated guidelines mean most gay and bisexual men who are in a monogamous relationship with another man will no longer need to abstain from sex to donate blood.

Previously, the FDA only allowed donations from men who have sex with men if they hadn’t had sex with another man for three months.

“The implementation of these recommendations will represent a significant milestone for the agency and the LGBTQI+ community,” Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said in a release.

The agency will continue to monitor the safety of the blood supply, he added.

The FDA’s restrictions on blood donations from men who have sex with men stem from the AIDS crisis, which began in the early 1980s, when little was known about HIV.

The agency first proposed the new rules, which are in line with those in Canada and the United Kingdom, in January.

People who are taking medication to prevent or treat an HIV infection would be asked to wait to donate blood under the new guidelines.



Source

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here
Health

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here

Wall Street is optimistic that Olema Pharmaceutical could be developing the next major breakthrough breast cancer treatment. Earlier this month, the company announced promising clinical data for its lead candidate palazestrant, an oral medication that is being evaluated in several trials for estrogen receptor-positive, or ER+, breast cancer. Shares of the clinical-stage biopharmaceutical company are up […]

Read More
This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’
Health

This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’

It’s been a stellar few months for shares of San Francisco-based biotech company Rigel Pharmaceuticals, which has approved treatments for rheumatology and oncology — as well as potential new drugs in the pipeline. The stock has jumped about 50% in just the last three months, earning it a spot on CNBC’s list of top performing […]

Read More
We’re raising our Eli Lilly price target — what a difference a quarter makes
Health

We’re raising our Eli Lilly price target — what a difference a quarter makes

Eli Lilly shares jumped Thursday after the drugmaker posted a strong third quarter, driven by sales of its popular GLP-1 medications. The company also raised its full-year sales outlook for the second time in a row, inspiring confidence in the trajectory of the franchise. Revenue in the three months ended Sept. 30 jumped 54% year […]

Read More